Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1973 1
1980 1
1982 2
1984 3
1986 2
1987 1
1988 1
1993 2
1994 1
1995 1
1996 3
1997 10
1998 10
1999 13
2000 29
2001 34
2002 50
2003 59
2004 82
2005 95
2006 114
2007 99
2008 141
2009 144
2010 210
2011 268
2012 326
2013 393
2014 484
2015 547
2016 525
2017 576
2018 584
2019 602
2020 690
2021 724
2022 706
2023 667
2024 633
2025 710
2026 436

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,895 results

Results by year

Filters applied: . Clear all
Page 1
Antitumor efficacy of repurposed phenformin in preclinical models of epithelial ovarian cancer.
Kim J, Choi JY, Seo JH, Cho YJ, Ryu JY, Hwang JR, Choi JJ, Lee JW. Kim J, et al. Biomed Pharmacother. 2026 Jul 9;201:119704. doi: 10.1016/j.biopha.2026.119704. Online ahead of print. Biomed Pharmacother. 2026. PMID: 42424918
Phenformin is a biguanide-class antidiabetic drug and has demonstrated anticancer activity in various malignancies. Epithelial ovarian cancer (EOC), which often develops chemoresistance, remains a lethal disease with a poor prognosis. While metformin has been widely …
Phenformin is a biguanide-class antidiabetic drug and has demonstrated anticancer activity in various malignancies. Epithelial ovarian ca …
Inflammaging and osteoarthritis - therapeutic opportunities.
Chan M, Low P, Ong SC, Choy SM, Lee WX, Goh KY, Ng KM, Chua K, Lee JY, Guo AK, Jia J, Tan EK, Tang HW, Chua K. Chan M, et al. Front Immunol. 2026 Jun 23;17:1850495. doi: 10.3389/fimmu.2026.1850495. eCollection 2026. Front Immunol. 2026. PMID: 42416050 Free PMC article. Review.
Recent studies have identified pharmacological and gene-based approaches that modulate SASP-related pathways. Small molecules such as anakinra, metformin, and rapamycin show potential in reducing inflammation and preserving cartilage, while microRNA modulation and CRISPR/C …
Recent studies have identified pharmacological and gene-based approaches that modulate SASP-related pathways. Small molecules such as anakin …
Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway.
Zhu L, Yang J, Li F, Wang D, Zhang W, Zhang J, Duan Z, Hu Y, Zhou Y. Zhu L, et al. Drug Des Devel Ther. 2026 Jul 3;20:544583. doi: 10.2147/DDDT.S544583. eCollection 2026. Drug Des Devel Ther. 2026. PMID: 42415939 Free PMC article.
RESULTS: Our study demonstrated that the combination of metformin and palbociclib synergistically inhibited proliferation and migration, and promoted apoptosis in HR+/HER2- breast cancer cells. ...Moreover, the metformin-palbociclib combination synergisticall …
RESULTS: Our study demonstrated that the combination of metformin and palbociclib synergistically inhibited proliferation and migrati …
Metformin-restricted motility of an NRF2-activated lung cancer cell line involves NAD+ depletion, rather than AMPK- or BACH1 signaling.
Cabrera SNS, Huber S, Braunböck-Müller B, Heiss EH. Cabrera SNS, et al. Sci Rep. 2026 Jul 7. doi: 10.1038/s41598-026-61444-3. Online ahead of print. Sci Rep. 2026. PMID: 42414524 Free article.
Instead, metformin reduced abundance of BACH1, a transcription factor not only competing with NRF2 but also favoring migration of cancer cells. ...Metformin, as mitochondrial complex I inhibitor, increased the cellular NADH/NAD+ ratio. ...
Instead, metformin reduced abundance of BACH1, a transcription factor not only competing with NRF2 but also favoring migration of …
Quality of life and patient-reported outcomes after non-surgical management of early-stage endometrial cancer and endometrial hyperplasia with atypia: a long-term follow-up of the feMMe phase II randomized clinical trial.
Steger K, Baxter E, Al Ramadhani R, Janda M, Obermair A. Steger K, et al. Int J Gynecol Cancer. 2026 Jun 11;36(9):104806. doi: 10.1016/j.ijgc.2026.104806. Online ahead of print. Int J Gynecol Cancer. 2026. PMID: 42413196
METHODS: The feMMe trial (open-label, randomized phase II study) includes three treatment arms: levonorgestrel intra-uterine device alone, levonorgestrel intra-uterine device plus weight loss, and levonorgestrel intra-uterine device plus metformin. Participants were contac …
METHODS: The feMMe trial (open-label, randomized phase II study) includes three treatment arms: levonorgestrel intra-uterine device alone, l …
Precise diagnosis of hepatocellular carcinoma and acute kidney injury through near-infrared imaging utilizing a fluorescence probe for monitoring α-l-fucosidase.
Mao CP, Tan JT, Wang K, Cai FF, Dai HB. Mao CP, et al. Anal Chim Acta. 2026 Sep 22;1416:345767. doi: 10.1016/j.aca.2026.345767. Epub 2026 May 30. Anal Chim Acta. 2026. PMID: 42401471
Additionally, we employed losartan and metformin to treat hyperuricemic nephropathy and diabetic nephropathy, respectively, and utilized the probe to achieve the screening and validation of therapeutic drugs. ...
Additionally, we employed losartan and metformin to treat hyperuricemic nephropathy and diabetic nephropathy, respectively, and utili …
Neoadjuvant metformin on clinical and pathological response in non-diabetic patients with non-metastatic breast cancer: an updated systematic review and meta-analysis.
Arriaga-Izabal D, Morales-Lazcano F, Angulo-Zamudio UA, Canizalez-Román A, León-Sicairos N. Arriaga-Izabal D, et al. Clin Transl Oncol. 2026 Jul 3. doi: 10.1007/s12094-026-04485-4. Online ahead of print. Clin Transl Oncol. 2026. PMID: 42399548 Review.
INTRODUCTION: Metformin has been explored as an anticancer agent in breast cancer, but randomized trial evidence remains inconsistent. This updated review evaluated neoadjuvant metformin's effect on response outcomes in non-diabetic patients with non-m …
INTRODUCTION: Metformin has been explored as an anticancer agent in breast cancer, but randomized trial evidence remains incon …
Effectiveness of Metformin in Preventing Colorectal Cancer Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation.
Hiroki S, Fukasawa T, Honda M, Kawakami K. Hiroki S, et al. Pharmacoepidemiol Drug Saf. 2026 Jul;35(7):e70429. doi: 10.1002/pds.70429. Pharmacoepidemiol Drug Saf. 2026. PMID: 42399205
PURPOSE: Observational studies have repeatedly reported lower cancer incidence among metformin users than nonusers, but findings are inconsistent and often affected by issues such as immortal time, unclear comparators, and use of total cancer as a composite o …
PURPOSE: Observational studies have repeatedly reported lower cancer incidence among metformin users than nonusers, but findin …
Metabolic reprogramming underlying the synergistic effect of energy metabolism inhibitors and chemotherapeutics in TNBC.
Zou T, He X, Jiang Z, Gao Y, Ding F, Gu J. Zou T, et al. Biochem Pharmacol. 2026 Jul 3;252:118216. doi: 10.1016/j.bcp.2026.118216. Online ahead of print. Biochem Pharmacol. 2026. PMID: 42398864
Triple-negative breast cancer (TNBC) is characterized by aggressive behavior and metabolic plasticity, limiting the efficacy of standard chemotherapy. ...Through cell viability screening, we identified two potent synergistic regimens: gemcitabine with metformin and …
Triple-negative breast cancer (TNBC) is characterized by aggressive behavior and metabolic plasticity, limiting the efficacy of stand …
8,895 results